Antibodies in development

In France, studies have revealed the presence ofHSV-1 antibodies in 70% of the population and HSV-2 antibodies in 17% of subjects. Overall, 20% of subjects test positive for anti-HSV-2 antibodies in developed countries, and this rate can reach 60% in developing countries. In France, labial herpes, or cold sores, affect around 12 million people. 

A recent example of an anticancer antibody in development that functions via apoptosis is 1D09C3, a HuCAL-derived antibody specific for human leukocyte antigen (HLA)-DR [111, 112], which is highly expressed in B and T cell lymphomas. At the time of writing, this antibody is about to enter clinical trials for B cell lymphomas. The antibody causes cell killing selectively in activated tumor cells without the need for exogenous effector cells, via a mechanism that is caspase independent. 

---